Somewhere in England this week, a patient with worsening breathlessness will be told there is no spirometry slot available for months. They will join a queue that already runs to roughly 600,000 people waiting for a formal COPD diagnosis, in a system where more than half of NHS regions lack the capacity to meet demand for the test itself. That test, forceful exhalation captured through specialist equipment, was designed in the nineteenth century and still takes the best part of an hour once training, administration and recovery are counted in. It is against that backdrop, not against the abstract promise of artificial intelligence in medicine, that TidalSense's latest funding round should be read.

The Cambridge company has raised £16 million, taking its total funding to £34 million, including a reported £9 million in grants from bodies such as NIHR, Innovate UK and Asthma and Lung UK. The money will accelerate commercial rollout of N-Tidal Diagnose, a handheld device that reads a patient's normal breathing for 75 seconds and uses AI models trained on more than 2.5 million recorded breaths to flag COPD, already commissioned by Suffolk and North East Essex ICB and in use at NHS Wales, Glasgow and community lung screening clinics in the south of England. The commercial logic is straightforward: a test that takes minutes rather than an hour, administered without specialist training, changes the arithmetic of who can be seen and how quickly, with clinicians able to assess four to six patients an hour against roughly one under conventional spirometry.

What makes the timing notable is not the size of the round but what NHS England published in the same period. A preliminary market engagement notice is now seeking industry input on the commercial and sourcing strategy for end-to-end diagnostic testing pathways attached to the NHS Online virtual hospital service, covering provider capability, digital maturity and interoperability requirements alongside digital test ordering and results notification. Read alongside TidalSense's expansion plans, this is not a case of a promising technology waiting for the system to catch up. It is a case of the system actively signalling the shape of the market it wants to buy into, at the precise moment a well-funded vendor with NHS deployment experience is scaling.

That convergence is where the genuine test lies, and it is not a technological one. TidalSense's diagnostic accuracy claims, above 90 per cent across key metrics in its first post-market validation at the European Respiratory Society congress, are a matter for regulators and clinicians to continue scrutinising. The harder question is whether NHS commissioning can move at the pace the funding suggests. The current pattern of adoption, one ICB here, a Welsh rollout there, a handful of community screening clinics in the south, is precisely the fragmented, locally negotiated commissioning model that has slowed previous digital health tools long after their clinical case was settled. A market engagement notice is a long way from a procurement framework, and NHS England has a track record of engagement exercises that inform strategy without translating quickly into funded, mandated adoption.

There is a workforce dimension too, understated in the coverage but material to delivery. Reducing a diagnostic pathway from an hour with a trained spirometry technician to minutes with any healthcare professional does not simply add capacity, it redistributes where diagnostic work happens, from acute respiratory departments into primary care and community settings already under their own pressure. That redistribution needs deliberate workforce planning, not just device rollout, if the promised gain in patients seen per hour is to be realised rather than absorbed into existing strain elsewhere in the pathway.

For NHS leaders and policymakers heading into an October Budget built around productivity, TidalSense's raise is a useful test case precisely because the money is not the obstacle. Private capital and grant funders have already made their judgement on the technology and the market. What remains unproven is whether NHS commissioning architecture, procurement discipline and workforce planning can convert a well-funded diagnostic tool into consistent national access rather than another regionally uneven pilot. The 600,000 people waiting for an answer will find out which it becomes.